GlassScriptPhysician profile
Seth R Lewis
NPI 1851409544
$1,820.95
in general payments reported to CMS, 2019-2025
22 companies · $15.64 in 2025
The $15.64 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $510 · 2020: $296 · 2021: $479 · 2022: $262 · 2023: $207 · 2024: $51.27 · 2025: $15.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $273.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $445.51 | 2019-2025 | Tradjenta, Synjardy, Jardiance |
| Abbvie INC. | $242.34 | 2021-2022 | |
| Astellas Pharma US INC | $169.73 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $160.28 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $119.63 | 2019-2022 | |
| Lilly USA, LLC | $112.68 | 2020-2024 | Zepbound, Mounjaro |
| Pfizer INC. | $100.96 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $69.38 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $62.53 | 2019 | |
| Amgen INC. | $59.33 | 2019 | |
| Allergan, INC. | $55.05 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $51.45 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $32.61 | 2023-2024 | Rexulti |
| Eisai INC. | $28.29 | 2020 | |
| Sumitomo Pharma America, INC. | $18.10 | 2023 | Gemtesa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $15.74 | 2023 | |
| Idorsia Pharmaceuticals US INC | $15.00 | 2023 | Quviviq |
| Novo Nordisk INC | $13.85 | 2019 | |
| Baxter Healthcare | $13.29 | 2023 | Hillrom - Vest System Model 105 Home Care |
| Sanofi-Aventis U.S. LLC | $12.41 | 2019 | |
| Glaxosmithkline, LLC. | $11.59 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.